Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Date:9/3/2007

DETROIT, Aug. 22 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Tablets USP, 37.5 mg (Phentermine HCl).

Phentermine HCl is indicated only as short-term monotherapy for the management of exogenous obesity. Our generic Phentermine HCl is the bioequivalent to Adipex-P(R), a registered trademark of TEVA Pharmaceuticals USA, Inc. According to IMS Data, for the twelve months ended June 2007, Phentermine HCl generic and brand products (Adipex-P(R)) combined had annual sales of approximately $34 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to gain this approval from the FDA. Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value. We plan to market this product to the generic pharmaceutical market immediately. This will bring our total product selection to 36 different products represented by 74 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2020)... ... August 11, 2020 , ... ... two new additions to its Safety Advisory Board: community-centered doctor and public health ... Anderson. , As the meaning of safety evolves with the COVID-19 pandemic, and ...
(Date:8/7/2020)... ... 07, 2020 , ... As part of their efforts to prioritize the well-being ... Bengtson Center team decided to temporarily suspend most in-person appointments, with the exception of ... the offices now open again, the leading plastic surgeons in Michigan —Dr. Brad ...
(Date:8/5/2020)... ... 2020 , ... Emotional ABCs , America’s most awarded ... inaugural list of Best Digital Tools for Teaching & Learning by the American ... provide enhanced learning and curriculum development for school librarians and their educator collaborators. ...
(Date:8/5/2020)... ... August 05, 2020 , ... Hypoglycemia (low blood glucose ... of hospital stay, or even death. A researcher at the VA Maryland Health ... diabetes to see if the use of continuous glucose monitoring devices can prevent ...
(Date:8/5/2020)... CAPE TOWN, South Africa (PRWEB) , ... August 05, 2020 , ... ... and Invest Africa , the leading trade and investment platform for Africa, announced ... groundbreaking agreement is for YPO Africa and Invest Africa to support each other in ...
Breaking Medicine News(10 mins):
(Date:8/5/2020)... ... August 05, 2020 , ... Our pets mean the world to us, and lately with ... same without the warmth, joy, and comfort they bring. National Dog Day is coming up ... with love and appreciation. , Set aside some time to do what they love most, ...
(Date:8/5/2020)... ... August 04, 2020 , ... Fifty six percent of older adults think ... effectively to a healthcare crisis like COVID-19, according to a new survey by The ... important issues for older voters this year,” says Mary Johnson, a Medicare, and Social ...
(Date:8/3/2020)... ... , ... PMI Advisors, a leading management consulting firm, announces ... These plans help ensure that companies actually function and survive should their ... as a result of sickness or injury. , A recent survey of closely-held ...
Breaking Medicine Technology: